The  ||| S:0 E:4 ||| DT
future  ||| S:4 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
sublingual  ||| S:14 E:25 ||| FW
immunotherapy  ||| S:25 E:39 ||| FW
Sublingual  ||| S:39 E:50 ||| FW
immunotherapy  ||| S:50 E:64 ||| FW
( ||| S:64 E:65 ||| -LRB-
SLIT ||| S:65 E:69 ||| NNP
)  ||| S:69 E:71 ||| -RRB-
is  ||| S:71 E:74 ||| VBZ
currently  ||| S:74 E:84 ||| RB
the  ||| S:84 E:88 ||| DT
most  ||| S:88 E:93 ||| RBS
prescribed  ||| S:93 E:104 ||| JJ
form  ||| S:104 E:109 ||| NN
of  ||| S:109 E:112 ||| IN
allergen  ||| S:112 E:121 ||| JJ
immunotherapy  ||| S:121 E:135 ||| NN
in  ||| S:135 E:138 ||| IN
many  ||| S:138 E:143 ||| JJ
European  ||| S:143 E:152 ||| JJ
countries ||| S:152 E:161 ||| NNS
.  ||| S:161 E:163 ||| .
Its  ||| S:163 E:167 ||| PRP$
use  ||| S:167 E:171 ||| NN
has  ||| S:171 E:175 ||| VBZ
been  ||| S:175 E:180 ||| VBN
accepted  ||| S:180 E:189 ||| VBN
in  ||| S:189 E:192 ||| IN
the  ||| S:192 E:196 ||| DT
international  ||| S:196 E:210 ||| JJ
consensus  ||| S:210 E:220 ||| NN
publications ||| S:220 E:232 ||| NNS
,  ||| S:232 E:234 ||| ,
and  ||| S:234 E:238 ||| CC
recently  ||| S:238 E:247 ||| RB
also  ||| S:247 E:252 ||| RB
the  ||| S:252 E:256 ||| DT
scepticism  ||| S:256 E:267 ||| NN
of  ||| S:267 E:270 ||| IN
USA  ||| S:270 E:274 ||| NNP
scientists  ||| S:274 E:285 ||| NNS
is  ||| S:285 E:288 ||| VBZ
attenuated ||| S:288 E:298 ||| VBN
.  ||| S:298 E:300 ||| .
Still ||| S:300 E:305 ||| RB
,  ||| S:305 E:307 ||| ,
this  ||| S:307 E:312 ||| DT
treatment  ||| S:312 E:322 ||| NN
may  ||| S:322 E:326 ||| MD
be  ||| S:326 E:329 ||| VB
improved ||| S:329 E:337 ||| VBN
,  ||| S:337 E:339 ||| ,
and  ||| S:339 E:343 ||| CC
the  ||| S:343 E:347 ||| DT
possible  ||| S:347 E:356 ||| JJ
developments  ||| S:356 E:369 ||| NNS
consist  ||| S:369 E:377 ||| VBP
of  ||| S:377 E:380 ||| IN
modification  ||| S:380 E:393 ||| NN
of  ||| S:393 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
materials ||| S:400 E:409 ||| NNS
,  ||| S:409 E:411 ||| ,
use  ||| S:411 E:415 ||| NN
of  ||| S:415 E:418 ||| IN
adjuvants  ||| S:418 E:428 ||| NN
and  ||| S:428 E:432 ||| CC
use  ||| S:432 E:436 ||| NN
of  ||| S:436 E:439 ||| IN
recombinant  ||| S:439 E:451 ||| JJ
allergens ||| S:451 E:460 ||| NN
.  ||| S:460 E:462 ||| .
Moreover ||| S:462 E:470 ||| RB
,  ||| S:470 E:472 ||| ,
new  ||| S:472 E:476 ||| JJ
applications  ||| S:476 E:489 ||| NNS
of  ||| S:489 E:492 ||| IN
SLIT ||| S:492 E:496 ||| NNP
,  ||| S:496 E:498 ||| ,
such  ||| S:498 E:503 ||| JJ
as  ||| S:503 E:506 ||| IN
food  ||| S:506 E:511 ||| NN
allergy ||| S:511 E:518 ||| NN
,  ||| S:518 E:520 ||| ,
seem  ||| S:520 E:525 ||| VBP
promising ||| S:525 E:534 ||| VBG
.  ||| S:534 E:536 ||| .
Concerning  ||| S:536 E:547 ||| VBG
materials ||| S:547 E:556 ||| NNS
,  ||| S:556 E:558 ||| ,
the  ||| S:558 E:562 ||| DT
future  ||| S:562 E:569 ||| JJ
form  ||| S:569 E:574 ||| NN
of  ||| S:574 E:577 ||| IN
SLIT  ||| S:577 E:582 ||| NNP
is  ||| S:582 E:585 ||| VBZ
likely  ||| S:585 E:592 ||| JJ
to  ||| S:592 E:595 ||| TO
be  ||| S:595 E:598 ||| VB
represented  ||| S:598 E:610 ||| VBN
by  ||| S:610 E:613 ||| IN
tablets ||| S:613 E:620 ||| NNS
,  ||| S:620 E:622 ||| ,
which  ||| S:622 E:628 ||| WDT
were  ||| S:628 E:633 ||| VBD
already  ||| S:633 E:641 ||| RB
tested  ||| S:641 E:648 ||| VBN
for  ||| S:648 E:652 ||| IN
efficacy  ||| S:652 E:661 ||| NN
and  ||| S:661 E:665 ||| CC
safety  ||| S:665 E:672 ||| NN
with  ||| S:672 E:677 ||| IN
grass  ||| S:677 E:683 ||| JJ
pollen  ||| S:683 E:690 ||| NN
extracts ||| S:690 E:698 ||| NN
,  ||| S:698 E:700 ||| ,
and  ||| S:700 E:704 ||| CC
are  ||| S:704 E:708 ||| VBP
likely  ||| S:708 E:715 ||| JJ
to  ||| S:715 E:718 ||| TO
increase  ||| S:718 E:727 ||| VB
the  ||| S:727 E:731 ||| DT
convenience  ||| S:731 E:743 ||| NN
for  ||| S:743 E:747 ||| IN
the  ||| S:747 E:751 ||| DT
patient  ||| S:751 E:759 ||| NN
by  ||| S:759 E:762 ||| IN
the  ||| S:762 E:766 ||| DT
use  ||| S:766 E:770 ||| NN
of  ||| S:770 E:773 ||| IN
no-updosing  ||| S:773 E:785 ||| JJ
schedule ||| S:785 E:793 ||| NN
.  ||| S:793 E:795 ||| .
Adjuvants  ||| S:795 E:805 ||| JJ
fitting  ||| S:805 E:813 ||| NN
with  ||| S:813 E:818 ||| IN
the  ||| S:818 E:822 ||| DT
characteristics  ||| S:822 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
SLIT  ||| S:841 E:846 ||| NNP
seem  ||| S:846 E:851 ||| VBP
to  ||| S:851 E:854 ||| TO
be  ||| S:854 E:857 ||| VB
CpG  ||| S:857 E:861 ||| JJ
oligodeoxynucleotides  ||| S:861 E:883 ||| NNS
( ||| S:883 E:884 ||| -LRB-
CpG ||| S:884 E:887 ||| NNP
) ||| S:887 E:888 ||| -RRB-
,  ||| S:888 E:890 ||| ,
able  ||| S:890 E:895 ||| JJ
to  ||| S:895 E:898 ||| TO
interact  ||| S:898 E:907 ||| VB
with  ||| S:907 E:912 ||| IN
the  ||| S:912 E:916 ||| DT
Toll-like  ||| S:916 E:926 ||| JJ
receptor  ||| S:926 E:935 ||| NN
9  ||| S:935 E:937 ||| CD
( ||| S:937 E:938 ||| -LRB-
TLR9 ||| S:938 E:942 ||| NNP
)  ||| S:942 E:944 ||| -RRB-
whose  ||| S:944 E:950 ||| WP$
activation  ||| S:950 E:961 ||| NN
induces  ||| S:961 E:969 ||| VBZ
a  ||| S:969 E:971 ||| DT
Th1-like  ||| S:971 E:980 ||| JJ
pattern  ||| S:980 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
cytokine  ||| S:991 E:1000 ||| JJ
release ||| S:1000 E:1007 ||| NN
,  ||| S:1007 E:1009 ||| ,
combination  ||| S:1009 E:1021 ||| NN
of  ||| S:1021 E:1024 ||| IN
1,25-dihydroxyvitamin  ||| S:1024 E:1046 ||| NNP
D3  ||| S:1046 E:1049 ||| NNP
plus  ||| S:1049 E:1054 ||| CC
dexamethasone  ||| S:1054 E:1068 ||| NNS
( ||| S:1068 E:1069 ||| -LRB-
VitD3-Dex ||| S:1069 E:1078 ||| NNP
) ||| S:1078 E:1079 ||| -RRB-
,  ||| S:1079 E:1081 ||| ,
and  ||| S:1081 E:1085 ||| CC
Lactobacillus  ||| S:1085 E:1099 ||| NNP
plantarum ||| S:1099 E:1108 ||| NN
.  ||| S:1108 E:1110 ||| .
The  ||| S:1110 E:1114 ||| DT
approach  ||| S:1114 E:1123 ||| NN
with  ||| S:1123 E:1128 ||| IN
recombinant  ||| S:1128 E:1140 ||| JJ
allergens ||| S:1140 E:1149 ||| NN
,  ||| S:1149 E:1151 ||| ,
named  ||| S:1151 E:1157 ||| VBN
component-resolved  ||| S:1157 E:1176 ||| JJ
diagnosis ||| S:1176 E:1185 ||| NN
,  ||| S:1185 E:1187 ||| ,
offers  ||| S:1187 E:1194 ||| VBZ
the  ||| S:1194 E:1198 ||| DT
possibility  ||| S:1198 E:1210 ||| NN
to  ||| S:1210 E:1213 ||| TO
tailor  ||| S:1213 E:1220 ||| VB
immunotherapy ||| S:1220 E:1233 ||| NNS
,  ||| S:1233 E:1235 ||| ,
which  ||| S:1235 E:1241 ||| WDT
was  ||| S:1241 E:1245 ||| VBD
found  ||| S:1245 E:1251 ||| VBN
to  ||| S:1251 E:1254 ||| TO
be  ||| S:1254 E:1257 ||| VB
effective  ||| S:1257 E:1267 ||| JJ
in  ||| S:1267 E:1270 ||| IN
two  ||| S:1270 E:1274 ||| CD
randomized  ||| S:1274 E:1285 ||| CD
trials  ||| S:1285 E:1292 ||| NNS
of  ||| S:1292 E:1295 ||| IN
subcutaneous  ||| S:1295 E:1308 ||| JJ
SIT  ||| S:1308 E:1312 ||| NNP
( ||| S:1312 E:1313 ||| -LRB-
16-17 ||| S:1313 E:1318 ||| NNP
) ||| S:1318 E:1319 ||| -RRB-
,  ||| S:1319 E:1321 ||| ,
while  ||| S:1321 E:1327 ||| IN
studies  ||| S:1327 E:1335 ||| NNS
with  ||| S:1335 E:1340 ||| IN
SLIT  ||| S:1340 E:1345 ||| NNP
are  ||| S:1345 E:1349 ||| VBP
not  ||| S:1349 E:1353 ||| RB
yet  ||| S:1353 E:1357 ||| RB
available ||| S:1357 E:1366 ||| JJ
.  ||| S:1366 E:1368 ||| .
Regarding  ||| S:1368 E:1378 ||| VBG
food  ||| S:1378 E:1383 ||| NN
allergy ||| S:1383 E:1390 ||| NN
,  ||| S:1390 E:1392 ||| ,
an  ||| S:1392 E:1395 ||| DT
important  ||| S:1395 E:1405 ||| JJ
controlled  ||| S:1405 E:1416 ||| JJ
study  ||| S:1416 E:1422 ||| NN
demonstrated  ||| S:1422 E:1435 ||| VBN
that  ||| S:1435 E:1440 ||| IN
SLIT  ||| S:1440 E:1445 ||| NNP
with  ||| S:1445 E:1450 ||| IN
hazelnut  ||| S:1450 E:1459 ||| NN
is  ||| S:1459 E:1462 ||| VBZ
able  ||| S:1462 E:1467 ||| JJ
to  ||| S:1467 E:1470 ||| TO
increase  ||| S:1470 E:1479 ||| VB
patients  ||| S:1479 E:1488 ||| NNS
tolerance  ||| S:1488 E:1498 ||| NN
over  ||| S:1498 E:1503 ||| IN
possible  ||| S:1503 E:1512 ||| JJ
reactions  ||| S:1512 E:1522 ||| NNS
from  ||| S:1522 E:1527 ||| IN
inadvertent  ||| S:1527 E:1539 ||| JJ
assumption  ||| S:1539 E:1550 ||| NN
of  ||| S:1550 E:1553 ||| IN
the  ||| S:1553 E:1557 ||| DT
culprit  ||| S:1557 E:1565 ||| NN
food ||| S:1565 E:1569 ||| NN
,  ||| S:1569 E:1571 ||| ,
and  ||| S:1571 E:1575 ||| CC
warrants  ||| S:1575 E:1584 ||| NNS
for  ||| S:1584 E:1588 ||| IN
further  ||| S:1588 E:1596 ||| JJ
trials  ||| S:1596 E:1603 ||| NNS
with  ||| S:1603 E:1608 ||| IN
other  ||| S:1608 E:1614 ||| JJ
foods ||| S:1614 E:1619 ||| NNS
.  ||| S:1619 E:1621 ||| .
